Oramed (ORMP) COO Joshua Hexter gains 19,000 shares from performance unit vesting

Rhea-AI Filing Summary

Oramed Pharmaceuticals executive Joshua Hexter reported a share-based award vesting. On January 22, 2026, 19,000 performance stock units vested after Oramed’s common stock reached a specified price target. Each unit converted into one common share, giving Hexter 19,000 shares received for no cash consideration.

Following this conversion, Hexter directly holds 1,064,495 shares of Oramed common stock. The performance stock units were granted on December 31, 2025, and no derivative units of this grant remain outstanding after the vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hexter Joshua

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & CBO

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		M		19,000(1)	A	$0(1)	1,064,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	01/22/2026		M			19,000	(2)	(2)	Common Stock	19,000	$0	0	D

Explanation of Responses:

1. Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

2. Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

	/s/ Joshua Hexter	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oramed (ORMP) report for Joshua Hexter?

Oramed reported that executive Joshua Hexter had 19,000 performance stock units vest and convert into 19,000 shares of common stock. The vesting occurred when Oramed’s share price met specified performance criteria on January 22, 2026, and did not involve any cash payment.

How many Oramed (ORMP) shares does Joshua Hexter own after this Form 4?

After the reported transaction, Joshua Hexter directly beneficially owns 1,064,495 shares of Oramed common stock. This total reflects the addition of 19,000 shares received from vested performance stock units, which converted into common stock at no cash cost to Hexter.

What are performance stock units (PSUs) in Oramed’s Form 4 for ORMP?

In this filing, each Oramed performance stock unit represented a contingent right to receive one share of common stock. The PSUs vested only after the company’s stock achieved specified performance criteria, at which point 19,000 units converted into 19,000 shares for the reporting executive.

Did Joshua Hexter pay anything for the Oramed (ORMP) shares received?

No, Joshua Hexter did not pay cash for the shares. The Form 4 notes that 19,000 shares of Oramed common stock were received for no consideration when the performance stock units vested after the stock reached a specified price threshold set in the award terms.

What happened to Joshua Hexter’s outstanding PSUs in this Oramed (ORMP) filing?

The 19,000 performance stock units granted on December 31, 2025 vested on January 22, 2026 and converted into common shares. After this vesting event, the Form 4 shows zero derivative securities of this PSU grant remaining beneficially owned by Joshua Hexter.

What role does Joshua Hexter hold at Oramed Pharmaceuticals (ORMP)?

According to the Form 4, Joshua Hexter serves as an officer of Oramed Pharmaceuticals with the title COO & CBO. The reported transaction reflects equity compensation tied to his executive role, involving performance-based stock units that converted into common shares upon vesting.